lala

II CONGRESO COLOMBO-VENEZOLANO DE GINECOOBSTETRICIA . CUCUTA, NOVIEMBRE 2005

PERDIDA GESTACIONAL RECURRENTE

DEFINICION ,[object Object],[object Object],ACOG , 2001

INCIDENCIA ,[object Object],[object Object],[object Object],[object Object],[object Object],Kujovich - AJOG, Agosto/2004 Fauset-Branch/02 Saunders/2004

ETIOLOGIA ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES GENETICOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES GENETICOS ,[object Object],[object Object],[object Object],[object Object]

FACTORES GENETICOS ,[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES ENDOCRINOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],RCOG Guideline 17 – May 2003 CIGNA – Feb 2005.

FACTORES ENDOCRINOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES ANATOMICOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES INMUNOLOGICOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES INMUNOLOGICOS ,[object Object],[object Object],[object Object],[object Object],[object Object]

FACTORES INMUNOLOGICOS ,[object Object],[object Object],[object Object],[object Object]

FACTORES INMUNOLOGICOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

OTROS FACTORES ,[object Object],[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

SINDROME DE ANTICUERPOS ANTIFOSFOLIPIDOS ,[object Object]

PATOGENESIS ,[object Object],[object Object],[object Object],[object Object]

EPIDEMIOLOGIA ,[object Object],[object Object],[object Object],[object Object],[object Object]

CUADRO CLINICO ,[object Object],[object Object],[object Object]

S. A. A. F . ,[object Object],[object Object],[object Object],[object Object]

S. A. A. F . ,[object Object],[object Object],[object Object],[object Object],[object Object]

S.A.A.F. ,[object Object],[object Object],Autor Revista Resultados Laskin NEJM-1997 AAS sola v/s AAS + Prednisona 46.5% R.N.V. 53.5% R.N.V. Rai et al BMJ-1997 AAS sola v/s AAS + Heparina 42% R.N.V. 71 % R.N.V. Kutteh AJOG-2000 AAS sola v/s AAS + Heparina 44 % R.N.V. 80 % R.N.V.

S.A.A.F. ,[object Object],[object Object],[object Object]

TRATAMIENTO ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

EMBARAZO NORMAL ESTADO HIPERCOAGULABLE FIBRINOGENO Y FACTORES DE LA COAGULACION AUMENTADOS EXCEPTO FACTOR XI y XIII QUE ESTAN DISMINUIDOS EN LA PLACENTA EXISTE UN AUMENTO DEL INHIBIDOR DE ACTIVADOR DE PLASMINOGENO REDUCCION DE LA ANTICOAGULACION Y INHIBICION DE LA FIBRINOLISIS

EMBARAZO NORMAL TROMBOFILICO “PER SE” MAYOR RIESGO DE TROMBOSIS

TROMBOFILIAS Y EMBARAZO ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

DEFICIENCIA DE FACTORES ANTICOAGULANTES PRINCIPALES ,[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Resistencia a la Proteína C activada (Factor V Leiden) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

RESISTENCIA A LA PROTEINA C ACTIVADA SIN ANTECEDENTES DE TROMBOSIS CON ANTECEDENTES DE TROMBOSIS HEPARINIZACION PROFILACTICA HEPARINIZACION TERAPEUTICA

TROMBOFILIAS MIXTAS ,[object Object],[object Object],[object Object],[object Object],[object Object]

HIPERHOMOCISTEINEMIA ,[object Object],[object Object],[object Object]

COMPLICACIONES VINCULADAS A LOS ESTADOS TROMBOFILICOS ,[object Object],[object Object],[object Object],[object Object]

COMPLICACIONES MATERNAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

La Preeclampsia Severa, el D.P.P.N.I. y el R.C.I.U. son causas de Muerte Fetal Intrauterina, Parto de Pretérmino y severas complicaciones que pueden llevar a la muerte neonatal. Todas estas entidades tienen en común la lesión placentaria con isquemia. Es fisiopatológicamente descifrable que los estados trombofílicos tienen una alta chance de desencadenar más frecuentemente estas complicaciones por trombosis a nivel placentario.

COMPLICACIONES PLACENTERIAS ,[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object]

[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PREECLAMPSIA SEVERA ,[object Object],[object Object],[object Object],[object Object],[object Object]

[object Object],[object Object]

SCREENING PARA TROMBOFILIAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],FIRST LATINAMERICAN MEETING OF THROMBOPHILIA AND PREGNANCY COMPLICATIONS . Brasil , Abril 2002.

SCREENING PARA TROMBOFILIAS ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],FIRST LATINAMERICAN MEETING OF THROMBOPHILIA AND PREGNANCY COMPLICATIONS . Brasil , Abril 2002.

TRATAMIENTO ,[object Object],[object Object],[object Object]

TRATAMIENTO ,[object Object],[object Object]

CONCLUSIONES ,[object Object],[object Object],[object Object],[object Object]

CONCLUSIONES ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

PERDIDA GESTACIONAL RECURRENTE GRACIAS .

lala

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Similar a lala

Similar a lala (20)

Último

Último (20)

lala